Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Zedenoleucel by Marker Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval
Zedenoleucel is under clinical development by Marker Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
Data Insights
Zedenoleucel by Marker Therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Zedenoleucel is under clinical development by Marker Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...